A prospective observational study on the effect of Erythropoiesis stimulating agents in chronic kidney disease Anemia patients

Background and Objectives: Anemia is a frequent complication, and significant morbidity and mortality in patient with chronic kidney disease (CKD). Erythropoiesis Stimulating Agents (ESAs) have become the standard care for  anemia   t erapy and reduces need for blood transfusions. The bjective of the study was to evaluate the safety  and  effect  of  ESAs  and  to  create  the  awareness  among patients    regarding     the     Erythropoiesis     stimulating    agents     through    patient i formation leaflets. Methods: The prospective observational study of  6-month duration was conducted in a tertiary care hospital. A total of 162 patients on ESAs  were enrolled in the study. Patients were followed for continuously and the mean difference is assessed by monitoring the primary and secondary hematological parameters before and after ESAs administration. Patient information leaflet was given t the patients for education and awareness about ESAs. Results: Out of 162 patients, after the administration of ESAs mean value increase in hemoglobin level was found from base line 6.9g/dL to 11.6g/dL. Significant improvement was noted in CKD anemia patient indicating impact of patient counseli g. Conclusion: It can be  concluded that Erythropoiesis Stimulating Agents in treatment of anemia along with effective counseling from clinical pharmacist benefits CKD patients and improves the health outcomes.